



## Neelam Goyal, MD

Clinical Professor, Adult Neurology

 Curriculum Vitae available Online

### CLINICAL OFFICE (PRIMARY)

- **Stanford Neuroscience Health Center**

213 Quarry Rd

MC 5957 FI 2

Palo Alto, CA 94304

**Tel** (650) 723-5072      **Fax** (650) 725-7459

### Bio

---

#### BIO

Dr. Neelam Goyal earned her medical degree at SUNY Downstate in Brooklyn, NY. Subsequently, she completed her neurology residency, which included a chief year, followed by a fellowship year in neurophysiology, specializing in neuromuscular disorders and EMG nerve conduction studies at Stanford University Medical Hospital. After graduating, she joined the faculty of Stanford University School of Medicine in 2012. She is currently a Clinical Professor of Neurology and Neurological Sciences in the division of Neuromuscular Medicine.

Dr. Goyal focuses on the diagnosis, management, and electrophysiological testing of neuromuscular disorders, including SFEMG. Her expertise extends to immune-mediated disorders such as myositis, myasthenia gravis, CIDP, and vasculitis. Her research interests involve monitoring and managing the short and long-term toxicity of immunosuppressive agents. She is actively involved in a grant-supported project investigating steroid toxicity in patients with myasthenia gravis.

Currently, she serves as the Interim Vice Chair of Advancement, Community and Engagement, and the Wellbeing Director for the Neurology Department. Additionally, she acts as a communication coach for the Neurology residency program. Dr. Goyal is involved in various committees within Stanford, including the Clinical Assistant Professor Appointment and Promotions Committee and Health Information Management Committee. She also participates in multiple committees within the American Association of Neuromuscular and Neurodiagnostic Medicine (AANEM). Notably, she serves as the chair of the Scientific Committee for the Myasthenia Gravis Foundation of America and provides advisory support on various steering committees related to Myasthenia Gravis Therapeutics.

#### CLINICAL FOCUS

- Myasthenia Gravis
- Inclusion body myositis
- Neuromuscular Disorders
- Neurology

## ACADEMIC APPOINTMENTS

- Clinical Professor, Adult Neurology

## ADMINISTRATIVE APPOINTMENTS

- Interim Vice Chair, Advancement, Community and Engagement (ACE), Department of Neurology, (2024- present)
- Director, Wellbeing Director, Department of Neurology, (2022- present)
- Communication Coach, Stanford Neurology Residency Program, (2022- present)
- Member, Health Information Management Committee, Stanford Hospital & Clinics, (2020- present)
- Member, Clinical Assistant Professor Appointment and Promotions Committee, Office of Academic Affairs, (2020- present)
- Co-Director, Muscular Dystrophy Association Clinic, Stanford Hospital and Clinics, (2016-2022)

## HONORS AND AWARDS

- Stanford Leadership Development Program, Stanford University School of Medicine (2020-2021)
- Clinical Effectiveness Leadership Training, Stanford University School of Medicine (2019-2020)
- Robert Fisher Resident Teacher of the Year, Stanford University (2011)
- Alpha Omega Alpha Membership, SUNY Downstate (2006)

## BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Chair, Scientific Committee, Myasthenia Gravis Foundation of America (2023 - present)
- Member, American Academy of Neurology (AAN) (2008 - present)
- Member, Education Resource Committee, AANEM (2019 - present)
- Member, American Association of Neuromuscular Medicine (AANEM) (2012 - present)
- Member, Workshop Committee, AANEM (2019 - 2022)
- Member, Neuromuscular Medicine Self-Assessment Exam Committee, AANEM (2015 - 2018)
- Member, Muscular Dystrophy Association (2012 - 2022)

## PROFESSIONAL EDUCATION

- Internship: NYU Grossman Long Island School of Medicine Internal Medicine (2008) NY
- Residency: Stanford University Dept of Neurology (2011) CA
- Fellowship: Stanford University Clinical Neurophysiology Fellowship (2012) CA
- Medical Education: SUNY Downstate School of Medicine Registrar (2007) NY
- Board Certification: Electrodiagnostic Medicine, American Association of Neuromuscular (2013)
- Board Certification: Neurology, American Board of Psychiatry and Neurology (2011)

## LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

## Research & Scholarship

---

### CURRENT RESEARCH AND SCHOLARLY INTERESTS

Dr. Goyal's research interests involve monitoring and managing the short and long-term toxicity of immunosuppressive agents used in the treatment of immune-mediated neuromuscular disorders. She is actively involved in a grant-supported project investigating steroid toxicity in patients with myasthenia gravis.

She also serves as the Wellbeing Co-Director for the Neurology Department, working on a grant-supported project aimed at mitigating the adverse impact of work on personal relationships.

## CLINICAL TRIALS

- A Study of TAK-079 in People With Generalized Myasthenia Gravis, Not Recruiting
- A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis, Not Recruiting

## PROJECTS

- Developing Department-Wide Policies and Best Practices for Limiting Impact of Work on Physician Vacation Time - Stanford University (9/1/2023 - present)
- Assessing Glucocorticoid associated toxicity in Myasthenia Gravis using Glucocorticoid Toxicity Index (GTI) - Stanford University (10/1/2023 - present)

## Publications

---

### PUBLICATIONS

- **Reduction in oral glucocorticoid use after efgartigimod initiation in clinical practice among patients with generalized myasthenia gravis.** *Journal of the neurological sciences*  
Goyal, N., Qi, C., Stone, J., Ruck, T., Wolfe, G. I., Smith, A. G., Gelin, D., Jefferson, M., Brauer, E., Suthagar, T. B., Menon, R. R., Sato, M., Phillips, et al  
2025; 477: 123652
- **Real-world Interaction Between Pregnancy and Generalized Myasthenia Gravis**  
Jackson, L., Zhdanova, M., Pesa, J., Boonmak, P., Jacobson, M., Libchaber, B., Lee, F., Pilon, D., Choudhry, Z., Goyal, N.  
LIPPINCOTT WILLIAMS & WILKINS.2025
- **Challenges to MG Clinical Trial Recruitment from a Tertiary Clinical Practice**  
Ngo, A., Katyal, N., Clifford, K., Lovall, M., Goyal, N., Muppidi, S.  
LIPPINCOTT WILLIAMS & WILKINS.2025
- **Streamlining Email Communications: Practical Wellbeing Support in a Digital World**  
Miller-Kuhlmann, R., Ng, S., Hoyte, E., Goyal, N., Gold, C.  
LIPPINCOTT WILLIAMS & WILKINS.2025
- **Hospitalization Outcomes After Efgartigimod Initiation in Patients with Myasthenia Gravis**  
Smith, A., Narayanaswami, P., Qi, C., Goyal, N., Mahajerin, A., Jefferson, M., Menon, R., Selvaraj, S., Sato, M., Wolfe, G.  
LIPPINCOTT WILLIAMS & WILKINS.2025
- **Changes in Nonsteroidal Immunosuppressive Treatment Usage Before and After Efgartigimod Initiation in Patients with Myasthenia Gravis**  
Narayanaswami, P., Qi, C., Goyal, N., Smith, A., Mahajerin, A., Campbell, R., Jefferson, M., Menon, R., Selvaraj, S., Sato, M., Wolfe, G.  
LIPPINCOTT WILLIAMS & WILKINS.2025
- **Treatment-related Characteristics Among Younger Women with Generalized Myasthenia Gravis**  
Pesa, J., Jackson, L., Keenan, A., Campbell, N., Gibson, G., Conyers, J., Goyal, N.  
LIPPINCOTT WILLIAMS & WILKINS.2025
- **Ravulizumab use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice.** *Frontiers in neurology*  
Katyal, N., Govindarajan, R., Goyal, N., Muley, S., Muppidi, S.  
2024; 15: 1378080
- **Efgartigimod demonstrates consistent improvements in patients with generalized myasthenia gravis regardless of prior treatment failures**  
Siddiqi, Z., Rozsa, C., Sacca, F., De Bleecker, J. L., Verschuuren, J., Hoffmann, S., Vu, T., Bril, V., Murai, H., Brauer, E., Kerstens, R., Steeland, S., Ulrichs, et al  
ELSEVIER.2023

- **Safety and outcomes with efgartigimod use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice.** *Muscle & nerve*  
Katyal, N., Halldorsdottir, K., Govindarajan, R., Shieh, P., Muley, S., Reyes, P., Leung, K. K., Mullen, J., Milani-Nejad, S., Korb, M., Goyal, N. A., Mozaffar, T., Goyal, et al  
2023
- **Scapular Winging In Patients With Anti-Hydroxy Methyl Glutaryl CoA Reductase (HMGCR) Antibody Positive Immune Mediated Necrotizing Myopathy (IMNM): A Case Series**  
Katyal, N., Goyal, N.  
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Clinical Experience With Efgartigimod For Treatment Of Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis**  
Katyal, N., Halldorsdottir, K., Goyal, N., Govindarajan, R., Muppidi, S., Habib, A.  
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Response to "Polyradiculitis Complicating SARS-CoV-2 Vaccinations is Not Infrequent".** *The Neurohospitalist*  
Lanman, T., Wu, C., Cheung, H., Goyal, N., Greene, M.  
2023; 13 (2): 210-211
- **Current status of clinical outcome measures in inclusion body myositis: a systematised review.** *Clinical and experimental rheumatology*  
Roy, B., Lucchini, M., Lilleker, J. B., Goyal, N. A., Naddaf, E., Adler, B., Alfano, L. N., Malandraki, G. A., Focht Garand, K. L., Mochel, D., Badrising, U., Machado, P. M., Pagkatipunan, et al  
2023
- **Current status of clinical outcome measures in inclusion body myositis: a systematised review** *CLINICAL AND EXPERIMENTAL RHEUMATOLOGY*  
Roy, B., Lucchini, M., Lilleker, J. B., Goyal, N. A., Naddaf, E., Adler, B., Alfano, L. N., Malandraki, G. A., Garand, K., Mochel, D., Badrising, U., Machado, P. M., Pagkatipunan, et al  
2023; 41 (2): 370-378
- **Response to "Polyradiculitis Complicating SARS-CoV-2 Vaccinations is Not Infrequent"** *NEUROHOSPITALIST*  
Lanman, T., Wu, C., Cheung, H., Goyal, N., Greene, M.  
2022
- **Improving Patient Outcomes through Standardized Protocols when prescribing Glucocorticoids**  
Chang, T., Post, D., Goyal, N.  
LIPPINCOTT WILLIAMS & WILKINS.2022
- **IMPROVING PATIENT OUTCOMES THROUGH STANDARDIZED PROTOCOLS WHEN PRESCRIBING GLUCOCORTICIDS**  
Goyal, N., Chang, T.  
WILEY.2022: S23
- **Guillain-Barre Syndrome with Rapid Onset and Autonomic Dysfunction Following First Dose of Pfizer-BioNTech COVID-19 Vaccine: A Case Report** *NEUROHOSPITALIST*  
Lanman, T., Wu, C., Cheung, H., Goyal, N., Greene, M.  
2022
- **Investigating Late-Onset Pompe Prevalence in Neuromuscular Medicine Academic Practices** *NEUROLOGY-GENETICS*  
Wencel, M., Shaibani, A., Goyal, N. A., Dimachkie, M. M., Trivedi, J., Johnson, N. E., Gutmann, L., Wicklund, M. P., Bandyopadhyay, S., Genge, A. L., Freimer, M. L., Goyal, N., Pestronk, et al  
2021; 7 (6)
- **Investigating Late-Onset Pompe Prevalence in Neuromuscular Medicine Academic Practices: The IPaNeMA Study.** *Neurology. Genetics*  
Wencel, M., Shaibani, A., Goyal, N. A., Dimachkie, M. M., Trivedi, J., Johnson, N. E., Gutmann, L., Wicklund, M. P., Bandyopadhyay, S., Genge, A. L., Freimer, M. L., Goyal, N., Pestronk, et al  
2021; 7 (6): e623
- **Exome testing most useful for people with recessive CMT**  
Siskind, C., Sampson, J., Goyal, N., Rocha, A., Day, J.  
WILEY.2021: 141-42

- **Response Rates in Placebo arm of MG Clinical Trials**

Muppidi, S., Samara, V., Lin, K., Goyal, N.  
LIPPINCOTT WILLIAMS & WILKINS.2019

- **Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. *Muscle & nerve***

Muppidi, S., Utsugisawa, K., Benatar, M., Murai, H., Barohn, R. J., Illa, I., Jacob, S., Vissing, J., Burns, T. M., Kissel, J. T., Nowak, R. J., Andersen, H., Casasnovas, et al  
2019

- **Making sense of antisense oligonucleotides: A narrative review *MUSCLE & NERVE***

Goyal, N., Narayanaswami, P.  
2018; 57 (3): 356–70